When are randomized controlled trials needed to assess novel anticancer drugs? An illustration based on the development of selpercatinib, a RET inhibitor

J. Gill, V. Prasad

Research output: Contribution to journalEditorial

Original languageEnglish (US)
Pages (from-to)328-330
Number of pages3
JournalAnnals of Oncology
Volume31
Issue number3
DOIs
StatePublished - Mar 2020

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this